Eli Lilly & Co. developed and manufactures Cialis, a drug which treats erectile dysfunction. Eli Lilly has had an ongoing patent dispute with other companies producing generic versions of Cialis about the Eli Lilly’s patent on the unit dose of Cialis. The companies have now reached a settlement deal with Eli Lilly over the Cialis patent. The settlement deal will result in Cialis coming off exclusive patent in 2018 instead of 2020 which was when the patent was going to expire.
Although this settlement deal will result in a loss of revenues on Cialis for Eli Lilly post 2018 it means that Eli Lilly can in return have guaranteed US marketplace exclusivity for Cialis until then which will be beneficial.